{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041578","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.212349+00:00","generated_at":"2026-06-11T14:56:31.977708+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pyxis Oncology to merge with Apexigen in stock deal; Pyxis shareholders to own 90% of combined company","bullets":["Exchange ratio: 0.1725 Pyxis shares per Apexigen share; combined ownership ~90% Pyxis, ~10% Apexigen.","Estimated purchase price ~$15.1M based on Pyxis closing price of $3.19 on June 5, 2023.","Pro forma combined net loss for FY2022: $158.9M; for Q1 2023: $25.3M.","Pro forma combined cash and marketable securities ~$161.4M as of March 31, 2023.","Apexigen options, RSUs, and warrants assumed and converted with substantially similar terms."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041578","json":"https://secwatch.observer/filing/0000950170-23-041578.json","markdown":"https://secwatch.observer/filing/0000950170-23-041578.md","text":"https://secwatch.observer/filing/0000950170-23-041578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023041578/0000950170-23-041578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023041578/pyxs-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:56:31.977708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}